Mark Lerner and his wife, Traci, co-chaired the Johns Hopkins Children’s Center Advisory Board, spearheading a campaign that raised more than $100 million needed to build a new Children’s and Maternal Health Hospital.
Rich Levy was Incyte’s first drug development employee.
It was Paul Friedman’s idea that the HIV drug Sustiva®, which failed in its initial trial, could be a powerful drug for patients if combined with other therapies.
Skip Klein is a very accomplished amateur photographer.
At Gliknik, we believe work ought to be fun and intense, and should provide opportunities to learn and to grow.
Gliknik has raised $23 million of equity and $33 million of non-dilutive capital.
Manu Mérigeon worked at BioRad in France for 10 years.
Many cancer therapeutic vaccines have advanced to clinical testing. Unfortunately, most have not demonstrated success. Gliknik has taken learnings from that history and applied them to investigational vaccine candidate GL-0817.
Jeff Herpst has 20 years’ experience in clinical operations and has held clinical development roles of increasing responsibility.
For several years, Gliknik CEO David Block headed the DuPont Merck commercial team that brought the HIV drug Sustiva® to commercialization.